Aeterna Zentaris Reports First Quarter 2024 Financial Results
14 mai 2024 18h00 HE
|
Aeterna Zentaris Inc
Company ended the quarter with $29.5 million in cashDETECT-trial recruitment completed; Company continues to expect the completion of the trial in the second quarter and top-line data in the third...
Unveiling the Potential: Beta-Glucan Market Trends and Future Insights
08 mai 2024 04h00 HE
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, May 08, 2024 (GLOBE NEWSWIRE) -- Beta-glucan is a type of soluble fiber found naturally in foods like oats, barley, mushrooms, and certain yeasts. It is a polysaccharide composed of glucose...
Aeterna Zentaris Announces Effective Date of Share Consolidation
01 mai 2024 07h55 HE
|
Aeterna Zentaris Inc
TORONTO, ON, May 01, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) announces that it has filed articles of amendment to effect the previously...
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
29 avr. 2024 09h00 HE
|
Ceapro Inc.
– 2023 marked by Ceapro’s achievement of key milestones and progress toward its next phase of growth – R&D activities focused on advancement of avenanthramide Phase 1-2a clinical study and...
Lily AI’s Co-Founders Purva Gupta and Sowmiya Chocka Narayanan Make Inc.’s 2024 Female Founders List
09 avr. 2024 09h15 HE
|
Lily AI
Lily AI’s Co-Founders Purva Gupta and Sowmiya Chocka Narayanan Make Inc.’s 2024 Female Founders List.
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
28 mars 2024 07h55 HE
|
Aeterna Zentaris Inc
TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce...
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
28 mars 2024 07h55 HE
|
Ceapro Inc.
TORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to...
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
27 mars 2024 08h05 HE
|
Aeterna Zentaris Inc
- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into...
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
12 mars 2024 14h10 HE
|
Ceapro Inc.; Aeterna Zentaris Inc.
TORONTO and EDMONTON, Alberta, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to...
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
12 mars 2024 14h10 HE
|
Aeterna Zentaris Inc
TORONTO and EDMONTON, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce...